The Beacon (Audio)

The Beacon (Audio)

Por: H. Jack West, MD
Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.
75 episodios disponibles

Latest episodes of the podcast The Beacon (Audio)

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075) 08/03/2019
Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074) 05/03/2019
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073) 28/12/2018
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072) 21/12/2018
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071) 11/12/2018
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070) 09/12/2018
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069) 04/12/2018
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068) 02/12/2018
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067) 16/11/2018
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066) 14/11/2018
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065) 08/11/2018
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064) 06/11/2018
"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063) 07/09/2018
Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062) 04/09/2018
TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061) 31/08/2018
Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060) 29/08/2018
What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059) 27/08/2018
New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058) 24/08/2018
Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057) 22/08/2018
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056) 20/08/2018
1 2 3 4 Siguiente › Última »
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA